MET and colorectal carcinoma: Early data on ABBV-400, a c-MET-targeted ADC linked with telisotuzumab (topoisomerase 1 inhibitor), demonstrated a robust safety profile and ORR (61.9%) in CRC (NCT05029882, NCT06107413) (Table 1) [135].